PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant
DiscussionThe primary objective of PreCycle is to test the hypothesis of superiority for time to deterioration (TTD) in terms of DQoL = “Deterioration of quality of life” (FACT-G scale) in patients supported by an eHealth therapy management system (CANKADO active) versus in patients merely receiving eHealth-based information (CANKADO inform).EudraCT Number: 2016 –004191-22 (Source: Trials)
Source: Trials - May 17, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
Condition: Locally Advanced or Metastatic Breast Cancer Interventions: Drug: SPH4336 Tablets; Drug: SPH4336 Tablets Placebo Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 16, 2023 Category: Research Source Type: clinical trials
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
Conditions: Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer Interventions: Drug: Sacituzumab Govitecan-hziy; Drug: Paclitaxel; Drug: Nab-paclitaxel; Drug: Capecitabine Sponsor: Gilead Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 3, 2023 Category: Research Source Type: clinical trials
